Notification by Director

RNS Number : 2414G
e-Therapeutics plc
25 May 2017
 

E-THERAPEUTICS PLC

 

("e-Therapeutics" or the "Company")

 

NOTIFICATION BY DIRECTOR

 

Oxford, UK, 25 May 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that it was informed on 25 May 2017 by the Company's Chairman, Mr Iain Ross, that on the afternoon of 24 May 2017, Redx Pharma plc ("Redx"), the drug discovery and development company, announced that it had gone into administration.

 

Redx's shares were suspended from trading on AIM as at 4.35pm yesterday afternoon. Mr Ross was appointed Chairman of Redx on 1 May 2017.

 

This announcement is being made pursuant to the requirements of AIM Rule 17 and Schedule 2(g)(v) to the AIM Rules for Companies.

 

For further information, please contact:

 

Contacts:

 

e-Therapeutics plc

Ray Barlow, CEO

Steve Medlicott, Finance Director

 

Tel: +44 (0) 1993 883 125

www.etherapeutics.co.uk 

 

Numis Securities Limited

Michael Meade / Freddie Barnfield
  (Corporate Finance)

James Black (Corporate Broking)

 

Tel: +44 (0) 207 260 1000

www.numis.com

 

Instinctif Partners

Melanie Toyne-Sewell / Alex Shaw

Tel: +44 (0) 207 457 2020

Email: e-therapeutics@instinctif.com

 

 

About e-Therapeutics plc

e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform.  The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.

The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology.  The business model is to partner these preclinical drug candidates.

e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAOKPDDKBKDAPB
UK 100

Latest directors dealings